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Introduction
The HIV/AIDS pandemic continues to present a major health 
challenge for sub-Saharan Africa, In Ethiopia, adult HIV prevalence in 
2009 was estimated to be between 1.4% and 2.8%.[1,2]. The Government 
of Ethiopia launched fee-based antiretroviral treatment in 2003 and 
free HAART in 2005. As of July 2010, about 97,000 adults and 4,800 
children are accessing HAART services in the country. As HAART 
becomes more available in this region, we expect the prevalence of 
HIV-related ocular complications to reduce as seen in the developed 
world.
HIV-related eye disease may affect 50-75% of HIV infected people 
worldwide at some point during the course of their illness [3]. This 
generally takes the form of opportunistic infections that can affect any 
of the ocular tissues, from the eyelids to the retina. In particular, those 
conditions affecting the retina may lead to chronic visual impairment 
or blindness. The spectrum of HIV-related disease appears to differ 
by geographic location, with reports suggesting that infection-related 
retinitis is not as common in sub-Saharan Africa compared to 
industrialized countries and South Asia [4-6].
Before highly active antiretroviral therapy (HAART) was widely 
available in North America and Europe, 50%–75% of the HIV-infected 
individuals were estimated to develop non refractive visual problems 
at some point during the course of their illness and Cytomegalovirus 
(CMV) retinitis was the leading cause of vision loss [7,8]. The incidence 
of both ocular complications like Cytomegalovirus retinitis (CMVR) 
and of visual loss has dropped dramatically in these regions since 
HAART was made available [9].  
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The Immune Reconstitution Inflammatory Syndrome (IRIS) is a 
well recognised complication of Antiretroviral Therapy (ART), which 
may lead to the clinical deterioration of opportunistic infections due 
to the rapid restoration of immunological host responses during the 
initial weeks of treatment [10]. Immune recovery uveitis (IRU) is 
the predominant form of ocular IRIS and mainly occurs in patients 
with pre-existing CMVR at the time of ART initiation [11]. IRU is 
characterised by ocular inflammation following ART initiation and can 
result in visual loss from macular oedema, retinal neovascularisation 
and cataract [12,13]. With increasing availability of antiretroviral 
therapy, IRU may play a significant role in contributing to ocular 
morbidity. Identification and treatment of ocular disease prior to ART 
initiation is, therefore, important.
The estimated prevalence of HIV-related eye disease in Ethiopia 
is reported to be between 60% before free HAART was launched [14]. 
Given that two-thirds of HIV-infected individuals reside in sub-Saharan 
Abstract
Background: The ocular manifestations of HIV may lead to visual impairment or blindness. In Ethiopia, patients 
typically initiate antiretroviral treatment (ART) with low CD4 cell counts when the risk of ocular complications may be 
high. 
Objective: To determine the prevalence and types of HIV associated ocular conditions in patients referred for on 
HAART in Ethiopia. 
Methods: This cross-sectional study was undertaken between March 2010 and August 2010 at the ART clinic of 
Gondar University Hospital, Northwest Ethiopia. Ophthalmic examinations were performed on all consecutive patients 
satisfying the criteria for enrolment into the ART clinic irrespective of the presence or absence of ophthalmic/visual 
symptoms.
Results: Enrolled patients (n = 126), of these 70 (57.6%) were females with male to female ratio of 1:1.25 and 
had a median CD4 cell count of 183 cell/μL (inter-quartile range [IQR], 105-253 cells/μL). About 76.2% of the patients 
had either Stage I or II. Ninety one (72.3%) of the patients had a CD4 count more than 200 cells/µL at the time 
of examination. The prevalence of HIV-associated ocular disease was 21.4%. Retinal Microvasculopathy was the 
commonest finding seen in 9 (7%). The other ocular manifestations noted included: uveitis 4 (3.2%), ophthalmic Herpes 
Zoster 3 (2.4%), Seborrheic blepharitis 3 (2.4%) and Molluscum contagiosum 3 (2.4%). One patient was found to have 
disseminated Kaposi sarcoma that had involved the eyelids. 
Conclusion: The study demonstrates that HIV/AIDS affects the eyes patients on HAART. It is, hence, recommended 
that eye care should be a part of the package of medical care in the management of patients on HAART.
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Africa, the literature on the prevalence or incidence of visual loss due 
to HIV-related eye diseases in patients on HAART is quite limited. To 
our knowledge, there have been no studies to date in Ethiopia that have 
evaluated the prevalence of HIV-related ocular lesions in an unselected, 
ART population. In this study, we report ocular manifestations of HIV/
AIDS patients on HAART in Northwest Ethiopia.
Patients and Methods
A cross sectional study was conducted among patients who are 
on HAART at the ART clinic of Gondar University Hospital from 
November 2010 to February 2011 to determine the pattern and 
prevalence of ocular manifestations of HIV . Gondar University 
Hospital is located in Gondar town which is found 740Kms northwest 
from the capital, Addis Ababa. It is a tertiary referral hospital that serves 
5 million populations. The ART clinic has a total of 9,019 patients on 
follow up out of which 6,022 are currently on HAART. 
All patients attending the clinic over a 2-month period were 
recruited irrespective of ophthalmic symptoms or history or CD4 
count. A structured questionnaire was used to assess the socio 
demographic characteristics that include age, sex, literacy status, 
occupation and income of the patients. Medical informations were 
obtained by a combination of direct interview of the patient and 
review of medical case notes. Data obtained included baseline CD4, 
present CD4 count, WHO clinical stage, duration since HIV diagnosis, 
treatment for opportunistic infection and duration of HAART. 
None of this information was disclosed to personnel conducting the 
ophthalmic examination. Ophthalmic examinations were conducted 
by ophthalmologists (FA & YA). Ophthalmic diagnosis was made 
clinically based up-on slit lamp bio microscopic examination and 
dilated indirect ophthalmoscope. Relevant laboratory investigations 
and histopathologic studies were done when the clinical situations 
dictate. Visual impairment and blindness was defined as per recently 
revised WHO guidelines, where visual impairment is defined as 
presenting visual acuity of less than 6/ 18 (0.3 Log MAR), but equal to 
or better than 3/60 (0.05), and blindness as presenting visual acuity of 
3/60 or worse, in the better eye [15]. All patients who were clinically 
diagnosed were treated accordingly by ophthalmologists. Information 
was recorded on a pre-coded data collection form and the data were 
analyzed by SPSS version 15 and p-value less than 0.05 were considered 
as significant. 
Ethical issues 
This study was conducted according to the principles expressed 
in the Declaration of Helsinki. Ethical approval for this study was 
obtained from the Institutional Review Board of the University of 
Gondar. Informed consent was obtained from all subjects.
Results
One hundred and twenty-six consecutive HIV-infected 
participants on HAART (252 eyes) were examined (Table 1). The 
median age of the 126 patients was 40 years (range: 10-70 years), and 
83 (65.9%) patients were female. Majority of HIV patients with ocular 
manifestations 22(81.5) are unskilled workers. The main sources 
of referral to the ART clinic were health centers where patients had 
undergone HIV testing upon relevant history/ examination findings 
- patients were thus referred to the ART clinic of Gondar University 
Hospital to receive free ART and HIV management. The median CD4 
cell count of participants was 183 cells/μL (Interquartile Range [IQR], 
105-253 cells/μL; range, 10 - 521 cells/μL).  About Ninety-six (76.2%) 
participants had symptomatic disease classified as WHO clinical stages 
Characteristic Participants with HIV-related ocular Conditions (%) (n=27)
Participants without HIV  
related Ocular conditions 
(%) (n=99)
Age in Years
<20 0 2(2.0)
20-30 7(25.9) 16(16.2)
31 -40 6(22.2) 36(36.4)
41 -50 9(33.3) 34(34.3)
> 51 5(18.6) 11(11.1)
Gender 
Male 10 (37.0) 33 (33.3)
Female 17 (63.0) 66 (66.7)
Occupation 
Skilled  2(7.4) 11(11.1)
Unskilled  22(81.5) 81(81.8)
None  3(11.1) 7(7.1)
Marital status
Single 5 ( 18.5) 19 (19.2)
Married 9 (33.3) 26 (26.3)
Divorced 10 (37.0) 28 ( 28.3)
Widowed 3 (11.1) 26 (26.3)
Table 1: Socio demographic Characteristics of patients who are on HAART in 
Gondar University Hospital, Northwest Ethiopia, 2010 (n=126).
*P<0.01
Table 2: Clinical Profile of patients who are on HAART in Gondar University 
Hospital, Northwest Ethiopia 2010 (n=126).
Clinical Parameter 
Participants with 
HIV-related ocular 
Conditions (%) (n=27)
Participants without 
HIV-related ocular 
Conditions (%) (n=99)
CD4 count (cells/μ L)
0-50 0 2(2.0)
51-200 6(22.2) 17(17.2)
201-500 13(48.1) 56(56.6)
>500 7(25.9) 15(15.2)
Not determined 1(3.7) 9(9.1)
WHO clinical stage*
I 15(55.6) 65(65.7)
II 8(29.6) 8(8.1)
III 4(14.8) 18(18.2)
IV 0 8(8.1)
Months since HIV 
diagnosis
<12 2(7.4) 6(6.1)
13-24 7(25.9) 33(33.3)
25-60 16(59.3) 49(49.5)
>61 2(7.4) 11(11.1)
Months since ART started
<12 1(3.7) 12(12.1)
13-24 7(25.9) 30(30.3)
25-60 18(66.7) 51(51.5)
>61 1(3.7) 6(6.1)
Tuberculosis status
No history 13(48.1) 54(54.5)
Past history 12(44.4) 41(41.4)
Current on treatment 2(7.4) 4(4.0)
History of eye symptoms
None 4(14.8) 16(16.2)
Reduced vision 11(40.7) 53(53.5)
Pain 11(40.7) 28(28.3)
Floaters 1(3.7) 2(2.0)
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I and II and nearly half (46.8%) had either current or a previous history 
of tuberculosis (pulmonary and extra-pulmonary).
In this study we found a total of 27 (21.4%) patients who had 
ocular manifestation of HIV/AIDS. Retinal Microvasculopathy 
was the commonest finding seen in 9 (7%) patients that was seen as 
cotton wool spot in different retinal quadrants with or without retinal 
hemorrhages. Other systemic conditions like systemic hypertension 
and diabetes mellitus were ruled out in such condition. There were 4 
cases with uveitis out of which toxoplasmosis retinochoroiditis was 
diagnosed in 3 (2.4%) patients and one case was idiopathic anterior 
uveitis. Ophthalmic Herpes zoster was seen in 3 (2.4%) patients with 
different degree of severity. Seborrheic blepharitis in 3 (2.4%) patients 
and Molluscum contagiosum of the eyelids in 3 (2.4%) patients were 
the other clinical conditions observed. There was a case of disseminated 
Kaposi sarcoma that had involved the eyelids. We have also observed 
one case of conjunctival lymphoma.  There was also one case with anti 
TB related optic atrophy (Table 3). 
Table 4 describes the main eye complications of HIV and their 
relationship to CD4 count. From the total participants with ocular 
manifestations, nearly half (48.1%) have a CD4 count of 201-500 cells/
µL. Ocular complications were common among patients with higher 
CD4 count. From the 27 patients with ocular manifestations, retinal 
microvasculopathy was observed in 4 (14.8%), 3 (11.1%) and 2(7.4%) 
patients with CD4 counts of 201-500 cells/µL, 51-200 cells/µL and >500 
cells/µL, respectively. Majority of opportunistic infections was also 
found in 6 (22.2%) and 4 (14.8%) patients with CD4 counts of 201-500 
cells/µL and 51-200 cells/µL, respectively. 
Discussion 
This study evaluated the prevalence of ocular disease in HIV-infected 
patients on ART service in Ethiopia, regardless of whether patients 
reported ocular or visual symptoms. Ophthalmic manifestations of HIV 
were found in over a 21.4% of patients which lower prevalence than 
that reported (60%) before free HAART was launched in Ethiopia [14]. 
The incidence of CMVR at this institution has decreased significantly 
with the recent use of HAART therapy. This effect may be related to 
the aggressive use of HAART and associated immune recovery in this 
population of AIDS patients. Despite the reduced incidence of CMVR 
associated with immune recovery, new cases still continue to develop 
[28]. Moreover, new disease entities such as immune recovery uveitis 
(IRU) have emerged following the introduction of HAART.
The most common manifestations were Retinal Microvaculopathy, 
Uveitis, Ophthalmic Herpes zoster, Molluscum Contagiosum and 
Seborrheic blepharitis. This is almost similar to the frequency of ocular 
complications reported from a study done in Senegal [11], but was 
higher than previous reports from Brundi and Malawi (Table 3). 
From the overall prevalence of HIV-associated ocular disease in 
this population, (74.1%) had CD4 counts >200 cells/μL. This result 
showed that even though many support that ocular manifestations are 
more important in those with ocular complaints or CD4 counts lower 
than 200 [7,16,17], they are also seen in patients with high CD4 or those 
without any ocular complaints. These findings are important with 
regard to policies for screening of ocular disease prior to ART. Screening 
in this patient population is particularly important not only because 
of the high prevalence of disease in this highly immunocompromised 
patient group but also in view of the potential for worsening of ocular 
diseases due to ART-induced IRIS.
The fact that more than 74.1% of the patients had CD4 counts 
>200 cells/μL may partially explain for the higher occurrence of 
eye manifestations regardless of CD4 count in this study. In this 
study the most common ocular manifestation observed was Retinal 
Microvaculopathy (7.1%) which was also most common ocular 
manifestation in our previous cross-sectional study (24%) before 
initiation of HAART [14]. The lower prevalence of microvasculopathy 
(7.1%) as compared to our previous study noted in this study could 
be due to the fact that most of the patients were on HAART for a 
longer duration and the consequent decrease in the viral load may 
lead to a decline in the vasculopathy. Previous cross-sectional studies 
from other African countries show RM to be the most common, 
ranging between 10% and 42% [18]. A report from India found 
microvasculopathy in 50% of the study subjects [6]. The most common 
types of retinal microvasculopathy were cotton wool spots in different 
retinal quadrants with or without retinal hemorrhages but their 
magnitude may be underestimated because they are typically transient 
and asymptomatic as is the case with this study and others from other 
African countries.
The most likely causes of uveitis were determined clinically. Four 
of the patients had uveitis out of which toxoplasmosis retinochoroiditis 
was diagnosed in 3 (2.4%) patients and one case was idiopathic 
anterior uveitis. In this study membranes in the pupillary area were 
the most predominant feature in the anterior segment. This could be 
due to frequent recurrent uveitis episodes which have been reported 
as immune recovery ocular inflammation in HAART patients. The 
possibility of syphilis was considered less likely because serological tests 
were found to be negative in all the patients with uveitis. Tuberculosis 
was the most common systemic opportunistic disease in the study 
subjects though no evidence of ocular tuberculosis was noted in any 
of the patients with tuberculosis. Ruling out uveitis due to tuberculosis 
with a greater degree of certainty is difficult. Reports from other studies 
showed diagnostic challenges and underreporting regarding ocular 
involvement by tuberculosis and syphilis [19,29].
Table 3: Ocular manifestations related to HIV/AIDS in patients who are on HAART 
in Gondar University Hospital, Northwest Ethiopia, 2010.
Ocular diagnosis Number of Patients (%)
Retinal Microvaculopathy 9 (7.1)
Uveitis 4 (3.2)
Ophthalmic Herpes zoster 3 (2.4)
Molluscum Contagiosum 3 (2.4)
Seborrheic blepharitis 3 (2.4)
Kaposi Sarcoma of eyelid 1 (0.8)
Bacterial keratitis 1 (0.8)
Dry eye 1 (0.8)
Conjunctival lymphoma 1 (0.8)
Neuro-ophthalmic disorders (optic atrophy) 1 (0.8)
Total 27
RM: Retinal Microvasculopathy; OI: Opportunistic infections; DE: Dry Eye; NOD: 
Neuro-ophthalmological disorder
Table 4: Ocular manifestations related to HIV/AIDS in patients who are on HAART 
verses CD4 count in Gondar University Hospital, Northwest Ethiopia, 2010.
CD4 Count (cells/µL)
Complications
RM OI Tumors DE NOD
0-50 - - - - -
51-200 3 4 2 - -
201-500 4 6 - 1 1
>500 2 3 - - -
Not determined - 1 - - -
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Herpes zoster ophthalmicus accounted for 2.4% of the ocular 
findings in all HIV/AIDS patients which is lower than has previously 
been reported in HIV before introduction of HAART [14,20] 
highlighting the importance of effective HAART in reducing Herpes 
zoster.   In this study, it was found that Herpes zoster ophthalmicus 
to be an important cause of unilateral complications due to severe 
involvement of the eyes, late presentation of patients and failure of 
early referral of patients to ophthalmologists by primary health care 
professionals. 
Molluscum contagiosum was decreased by half from a previous 
report of 4.8% before free HAART was introduced in Ethiopia [14]. 
Molluscum contagiosum lesions healing may occur at the initial phase 
of treatment or later depending on the patient’s previous immunological 
state [21]; however, inflammatory Molluscum contagiosum could 
be a sign of IRIS after HAART; therefore, attention must be paid 
to the possible complications associated with the restoration of 
immunocompetence. 
Although Human Herpes Virus-8 (HHV-8) infection is highly 
prevalent in Ethiopian [22], the study participants almost never develop 
Kaposi sarcoma, except one case with disseminated Kaposi sarcoma 
that had involved the eyelids. This is in marked contrast to the strong 
correlation observed worldwide between HHV-8 seroprevalence and 
the incidence of Kaposi sarcoma [23]. Elucidation of the mechanism of 
this postulated resistance to HHV-8 tumorigenicity among Ethiopians 
should be a target of future study. 
In this study, there was no single case with CMVR. This in paradox 
to the very high rate of CMVR (7.8%) reported in India [24]. The very 
low prevalence of CMVR seen may not be a direct reflection of lower 
incidence, but possibly reflect that these patients die from systemic 
opportunistic infections before their CD4 counts fall low enough to 
allow the development of HIV-related eye disease [3-5]. The spectrum 
of HIV-related disease appears to differ by geographic location, with 
reports suggesting that infection-related retinitis is not as common in 
sub-Saharan Africa compared to industrialized countries and South 
Asia [4-6]. This remarkable difference might be explained by the high 
and early mortality in African patients and, moreover, many patients in 
Africa spend the last days of their lives at home when they are critically 
ill [3,25]. It is also possible that HIV subtype, racial variation and co-
morbid illnesses could contribute to the rarity of CMV retinitis in 
developing countries [26]. Being a cross sectional study, this study has 
taken into account the few number of HIV/AIDS patients and may not 
be representing the majority that spend the last days of their lives at home 
and in darkness. In one of the patients dry eye (keratoconjunctivitis 
sicca) syndrome was detected which may be related to HIV-mediated 
inflammation and damage of the accessory and major lacrimal glands 
[27]. Despite the shortcomings, the importance of thorough eye 
evaluation in resource limited areas has been shown to be helpful in the 
diagnosis of systemic illnesses with diagnostic challenges.
Conclusion
Current practice at several ART clinics in Ethiopia is to refer 
patients for an ophthalmic examination only upon complaint of 
ocular symptoms or after a physician has noted abnormal ocular signs 
on medical examination. Our findings highlight the need for routine 
baseline ophthalmic screening at the pre-ART stage. Conducting a 
full ophthalmic examination requires trained personnel and adequate 
resources that may be difficult or impossible to provide for all patients 
in resource-limited countries. However, where possible, we suggest all 
patients diagnosed to have HIV infection should undergo ophthalmic 
examination prior to commencing ART and during ART in order 
to reduce HIV-related ocular morbidity in the era of increased ART 
availability in Ethiopia. Even though the ocular manifestations are 
more important in those with ocular complaints or CD4 counts lower 
than 200, according to results of this study, they are also seen in patients 
with high CD4 or those without any ocular complaints.
With the advent of increased ART availability, life expectancy for 
HIV-infected persons is likely to improve. However, the burden of 
HIV-related ocular disease is likely to remain stable or even increase 
with possible immune reconstitution ocular complications. Strategies 
for screening high-risk populations for HIV-related ocular disease are 
needed as well as provision for the management and treatment of these 
conditions once detected. Finally, further work is indicated to formally 
evaluate the validity of patients’ symptoms in detecting different types 
of HIV associated ocular disease. 
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